JNJ-26481585, as a novel second-generation HDAC inhibitor, exhibits broad-spectrum antiproliferative activity in solid and hematologic cancer cell lines including ovarian tumor cell lines. Here, HDAC9 is linked to hematopoietic and lymphoid cell neoplasm.